Milliman：2025年米勒曼医疗指数报告（英文版）

In the 2024 MMI report, we identified U.S. Food and Drug Administration approvals for new drugs or new uses for existing drugs as well as increased utilization of glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, Wegovy, Mounjaro, and Zepbound, as drivers of prescription drug costs. We anticipate these market forces will continue to contribute meaningfully to prescription drug trends in 2025. We also anticipate the introduction of additional biosimilars—drugs made from livin